NEW
Ozempic

Ozempic

semaglutide

Manufacturer:

Novo Nordisk

Distributor:

Novo Nordisk
Concise Prescribing Info
Contents
Semaglutide
Indications/Uses
Adults w/ insufficiently controlled type 2 DM as an adjunct to diet & exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.
Dosage/Direction for Use
SC Initially 0.25 mg once wkly, increased to 0.5 mg once wkly after 4 wk. After at least 4 wk w/ 0.5 mg once wkly, can be increased to 1 mg once wkly to further improve glycaemic control.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be administered IV or IM. Not to be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients w/ CHF NYHA class IV; end-stage renal disease. Consider GI adverse reactions in patients w/ impaired renal function. History of pancreatitis; discontinue if pancreatitis is suspected or confirmed. Hypoglycaemia. Closely monitor patients w/ diabetic retinopathy treated w/ insulin. Women of childbearing potential are recommended to use contraception while on treatment. Not to be used during pregnancy (discontinue at least 2 mth before planned pregnancy) & lactation. Childn & adolescents <18 yr. Elderly ≥75 yr.
Adverse Reactions
Hypoglycaemia when used w/ insulin or sulfonylurea; nausea, diarrhoea. Hypoglycaemia when used w/ other OADs, decreased appetite; dizziness; diabetic retinopathy complications; vomiting, abdominal pain/distention, constipation, dyspepsia, gastritis, GERD, eructation, flatulence; cholelithiasis; fatigue; increased lipase & amylase, decreased wt.
Drug Interactions
Increased risk of hypoglycaemia w/ sulfonylurea or insulin. Potential to impact the rate of absorption of oral medicinal products that requires rapid GI absorption.
MIMS Class
ATC Classification
A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Ozempic soln for inj 1 mg/0.74 mL
Packing/Price
3 mL x 1's
Form
Ozempic soln for inj 0.25 mg/0.19 mL
Packing/Price
1.5 mL x 1's
Form
Ozempic soln for inj 0.5 mg/0.37 mL
Packing/Price
1.5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in